US FDA dismisses director of over-the-counter drugs office

On December 3, a federal official confirmed that the U.S. Food and Drug Administration (FDA) is reassigning Theresa Michele, who has led the agencys office for non-prescription drugs for several years, to a new leadership role. This change follows closely on the heels of FDAs drug evaluation head, Richard Pazdur, announcing his retirement, highlighting another significant leadership shift under U.S. Health Secretary Robert F. Kennedy Jr.

Michele has directed the over-the-counter (OTC) drugs division since 2015, overseeing the review, approval, and regulation of products including pain relievers and flu remedies. According to the federal official, the FDA plans to restructure her former office with a greater emphasis on making medications more affordable.

Earlier reports from STAT News, citing internal sources, indicated that Michele informed her team during a staff meeting that she will be moving to a senior role at the FDAs Center for Medical Devices, effective Thursday. FDA Commissioner Marty Makary reportedly attributed Micheles reassignment to dissatisfaction with the pace of non-prescription drug approvals.

The FDA has been experiencing notable organizational changes, including leadership shifts, staff reductions, and initiatives to accelerate drug development. Analysts suggest these developments contribute to a perception of internal instability, which may affect confidence in the biotech sector.

Analysis: FDA's Leadership Shakeup and Its Implications for the Drug Approval Process

The recent reassignment of Theresa Michele, who has overseen the FDA’s Office for Non-Prescription Drugs since 2015, signals a significant change within the agency. This decision comes just days after Richard Pazdur, head of the FDA’s drug evaluation division, announced his retirement. These shifts in leadership under Health Secretary Robert F. Kennedy Jr. seem to indicate a broader effort to streamline operations, though they also raise questions about the FDA's stability and future direction.

Michele’s reassignment follows internal dissatisfaction with the pace of non-prescription drug approvals, according to FDA Commissioner Marty Makary. As she moves to a senior role at the Center for Medical Devices, the FDA plans to restructure the Office for Non-Prescription Drugs with a renewed focus on improving medication affordability. This restructuring could have a significant impact on how over-the-counter products, such as pain relievers and flu remedies, are reviewed and regulated moving forward.

While the FDA’s leadership shakeup reflects a desire for greater efficiency, it also highlights the challenges facing the agency in maintaining a steady course amid internal changes. The biotech sector, in particular, may be closely monitoring these developments, as any instability at the FDA could influence investor confidence and the pace of drug approvals.

Sources:

• US FDA removes longtime director of over-the-counter drugs office

Author: Lucas Grant
Lucas Grant is a sports journalist with extensive experience covering football and basketball championships. Known for factual accuracy and an engaging, dynamic writing style.